Iron ion chelating agent and application of medicinal salt of chelating agent

Abstract

The invention relates to the field of medicine, in particular to an iron ion chelating agent and application of medicinal salt of the chelating agent. According to the iron ion chelating agent and themedicinal salt thereof, the expression level of PD-L1 of the surfaces of multiple kinds of tumor cells can be effectively lowered, application of immunosuppression of multiple kinds of tumor cells, such as melanoma, bladder cancer, non-small cell lung cancer, bladder cancer, head and neck cancer, Hodgkin lymphoma, renal cell carcinoma and Merkel cell carcinoma, mediated by the PD-1 / PD-L1 passageis removed, and the application is different from novel application for treating diseases or symptoms caused by accumulation of excessive in-vivo iron ions.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of an iron ion chelating agent and a pharmaceutically acceptable salt thereof. For example, Deferasirox, Desferrioxamine, Deferiprone, L1NA11, Deferitrin or pharmaceutically acceptable salts thereof. Background technique [0002] Iron ion chelators include any pharmaceutically useful therapeutic agent for sequestering iron in patients in need of iron chelation, including 3,5-diphenyl-1,2,4-tri An azole derivative or a salt thereof, [0003] [0004] where R 1 and R 5 Simultaneously or independently of each other, hydrogen, halogen, hydroxyl, lower alkyl, halogen-lower alkyl, lower alkoxy, halogen-lower alkoxy, carboxyl, carboxyl, carbamoyl, N-lower alkylcarbamoyl , N,N-di-lower alkylcarbamoyl or nitrile; R 2 and R 4 Simultaneously or independently of each other is hydrogen, unsubstituted or substituted lower alkanoyl or aroyl or a group that can be removed under p...

AI Technical Summary

Problems solved by technology

Although PD-1 / PD-L1 immunotherapy has shown efficacy in a variety of cancer treatments, the above drugs are all antibody drugs. Compared with small molecule drugs, their preparation, storage, transportation and technical costs are higher, which lead to The cost of medication for patients is too high; in addition, the effective rate of this therapy for most cancers is only 20%-40%, and some patients will relapse after remission, which invisibly increases the pressure on patients, and some patients have to consider The “to use or not to use” question

Images